المؤلفون: McGuire DK; Division of Cardiology, University of Texas Southwestern Medical Center and Parkland Health and Hospital System, 5323 Harry Hines Blvd, Dallas, TX, 75235-8830, USA. darren.mcguire@utsouthwestern.edu., D'Alessio D; Division of Endocrinology, Duke University Medical Center, Durham, NC, USA., Nicholls SJ; Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Melbourne, Australia., Nissen SE; Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, OH, USA., Riesmeyer JS; Eli Lilly and Company, Indianapolis, IN, USA., Pavo I; Eli Lilly Regional Operations GmbH, Vienna, Austria., Sethuraman S; Eli Lilly and Company, Indianapolis, IN, USA., Heilmann CR; Eli Lilly and Company, Indianapolis, IN, USA., Kaiser JJ; Eli Lilly and Company, Indianapolis, IN, USA., Weerakkody GJ; Eli Lilly and Company, Indianapolis, IN, USA.

المصدر: Cardiovascular diabetology [Cardiovasc Diabetol] 2022 Aug 24; Vol. 21 (1), pp. 163. Date of Electronic Publication: 2022 Aug 24.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE

مواضيع طبية MeSH: Cardiovascular Diseases*/epidemiology , Diabetes Mellitus, Type 2*/drug therapy , Hypoglycemic Agents*/adverse effects, Bayes Theorem ; Drugs, Investigational/therapeutic use ; Glucagon-Like Peptide 1/adverse effects ; Glucagon-Like Peptide-1 Receptor/agonists ; Humans ; Randomized Controlled Trials as Topic ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Treatment Outcome